Click Therapeutics Launches CT-155 With New Commercial Control
Edited by Colin Smith — April 27, 2026 — Tech
This article was written with the assistance of AI.
References: mobihealthnews
Click Therapeutics secured $50 million in Series D funding from Boehringer Ingelheim to advance CT-155, its prescription digital therapeutic for adults with schizophrenia, featuring FDA Breakthrough Device designation and co-development with Boehringer.
The deal included an agreement transferring commercialization and marketing responsibility for CT-155 to Click, positioning the company to lead rollout efforts. CT-155 is designed as a clinician-prescribed software treatment to address schizophrenia symptoms through structured digital interventions; specifics on delivery and clinical protocols were included in the companies' announcement.
This shift matters because it pairs regulatory recognition with direct commercial stewardship, enabling Click to scale access and integrate CT-155 into existing care pathways, a growing trend where digital therapeutics move from pilot stages to market-ready medical treatments.
Image Credit: Click Therapeutics
The deal included an agreement transferring commercialization and marketing responsibility for CT-155 to Click, positioning the company to lead rollout efforts. CT-155 is designed as a clinician-prescribed software treatment to address schizophrenia symptoms through structured digital interventions; specifics on delivery and clinical protocols were included in the companies' announcement.
This shift matters because it pairs regulatory recognition with direct commercial stewardship, enabling Click to scale access and integrate CT-155 into existing care pathways, a growing trend where digital therapeutics move from pilot stages to market-ready medical treatments.
Image Credit: Click Therapeutics
Would you use prescription therapy apps?
Helps gauge willingness to try clinician-prescribed therapy apps, preferred access channels, and current behavior around digital mental health tools—informing coverage, product guides, and partnerships.
1 / 3
When was the last time you used an app for mental health support?
2 / 3
If a clinician prescribed a therapy app, would you try it?
3 / 3
Where would you be most likely to get a prescribed therapy app?
Trend Themes
-
Prescription Digital Therapeutics — Clinician-prescribed software therapies for conditions like schizophrenia create potential to replace or augment traditional pharmacological regimens with evidence-based digital interventions.
-
Regulatory-backed Software Treatments — FDA Breakthrough Device designations for digital therapeutics signal pathways for software to achieve formal medical-product status and reimbursement parity with hardware or drug therapies.
-
Commercial-control Shift to Developers — The transfer of commercialization responsibility to developers illustrates a move toward software-first companies leading market rollout and care-integration strategies previously handled by pharma partners.
Industry Implications
-
Pharmaceuticals — Drug companies face the prospect of combining or competing with regulated digital therapies that modify treatment protocols and influence prescribing behavior.
-
Mental Health Care — Behavioral health providers could see care pathways transformed by scalable, clinician-prescribed digital tools that standardize therapeutic delivery and monitoring.
-
Health Technology Platforms — Platform providers may become hubs for distributing regulated therapeutic software, supporting integrations with EHRs, outcomes monitoring, and payer billing systems.
7.5
Score
Popularity
Activity
Freshness
